Chemed (CHE)
(Delayed Data from NYSE)
$554.39 USD
+5.12 (0.93%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $554.63 +0.24 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$554.39 USD
+5.12 (0.93%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $554.63 +0.24 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters
The World Cup Begins: Global Week Ahead
by John Blank
We have lots of global events this week, counted in terms of soccer games, a historic diplomatic summit, and three major monetary policy meetings.
Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.
LHCG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LHCG vs. CHE: Which Stock Is the Better Value Option?
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Why Is Chemed (CHE) Up 13.6% Since Its Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why
by Zacks Equity Research
Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.
BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.
STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.
Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact
by Zacks Equity Research
We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.
Align Technology (ALGN) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.
Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.
Chemed (CHE) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Chemed Corporation is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for CHE for clues.
CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow
by Zacks Equity Research
CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.
ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
GNC Holdings (GNC) Beats on Q1 Earnings, Plans Store Shutdown
by Zacks Equity Research
GNC Holdings (GNC) announces plans to shutter roughly 200 stores in 2018 as part of the ongoing optimization of the company's store portfolio in Q1.
Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.
Varian Medical (VAR) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong performance in the Software, Hardware and Service revenues boost Varian Medical's (VAR) Q2 results.
CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance
by Zacks Equity Research
CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.
Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View
by Zacks Equity Research
Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.
Align Technology (ALGN) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.